Enhancing the Mass Spectrometry Characterization of Antibody Drug Conjugates (ADCs)
27 Sep 2016
Antibody-drug conjugates (ADCs) are a new class of biotherapeutics that represent a rapidly growing portion of the drug discovery pipeline in pharmaceutical companies. ADCs are monoclonal antibodies chemically linked to biologically active small molecule drugs. By combining potent cytotoxic drugs with target-specific antibodies, ADCs deliver cytotoxic drugs to the diseased tissue while limiting the toxicity in the nontargeted tissues.
Drug-to-antibody ratio (DAR) is the average number of drugs conjugated to the antibodies, which is an important attribute of ADCs. The DAR value affects the efficacy of the drug, as low drug loading reduces the potency, while high drug loading can negatively affect pharmacokinetics and toxicity.
In this webinar, Mike Peddicord, Senior Research Scientist II, Bristol-Myers Squibb, will discuss:
- How intact mass LC-MS data is used to determine drug-to-antibody (DAR) ratios, and some ways that this information can be used to drive decisions in the development of ADCs
- A look back at some older methods of determining the DAR value from an LC-MS data set, and how these methods were time-consuming, and not always user-friendly
- Why the Agilent DAR calculator is a great software tool to enhance the speed of data processing and data reporting for LC-MS intact mass measurements of ADCs